Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product ...

(Bloomberg) -- Just when it looked like the worst was over for the Spanish family behind one of the world’s biggest medical fortunes, its financial woes plumbed to a new low. The Grifols family ...

Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago.

Brookfield Asset Management is awaiting information from Grifols SA about related-party transactions as it seeks to complete its due diligence on the business, according to a person familiar with ...

European shares struggle ahead of speeches from ECB policymakers 9:30 AM UTC Canadian fund Brookfield plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols after ...

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% ...

Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion. Operations ...

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular surface immunoglobulin eye drops for their ability to ...

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis Grifols surgical bleeding management ...

Brookfield still hasn't managed to obtain the €9.5 billion of bank financing to repay Grifols’ debt, nor the €3.5 billion it ...